21SEP

Arrakis: Blossom's second lead in 3 days

1 min read

16:52UTC

Arrakis, a London AI company, raised £22.5m on 24 July led by Blossom Capital, three days after the same fund led a twenty-one-year-old propulsion firm.

← Back to Nscale takes $103.4bn of contracts to NYSE Jump to analysis ↓

TechnologyDeveloping

Key takeaway

Arrakis closed £22.5m without a public product, which at Series A scale is now unremarkable.

Arrakis, a London artificial-intelligence (AI) company, raised a £22.5 million Series A on Friday 24 July led by Blossom Capital, with the venture funds Accel, GFC, MainObject and Rerail following ¹.

That is Blossom's second Series A lead in three days. On the Tuesday it led a Bedford propulsion company with patents, aircraft customers and twenty-one years of trading behind it. On the Friday it led an AI company at seed-plus scale. One fund, two leads, opposite ends of the evidence spectrum.

The weekly roundup labels Arrakis an AI company and names no product or market, and we could not reach a company release ². That absence is itself ordinary now. AI companies took a record share of UK smaller-business equity value last year , and at Series A scale a round can close on a founding team and a thesis before anything ships. We report the cheque and the syndicate, and leave the rest until somebody publishes it.

Deep Analysis

In plain English

Arrakis is a London company working on artificial intelligence software. It raised £22.5m from investors including Accel and GFC, with Blossom Capital leading the round. This was Blossom's second time leading a funding round in just three days, having also led Bedford company Greenjets' £30m raise days earlier, showing the same investment fund actively writing large cheques into very different kinds of British technology companies in the same week.

Deep Analysis

Root Causes

A single fund leading two Series A rounds three days apart reflects how venture partnerships allocate capital, not a hot sector. Partners at a fund like Blossom Capital run independent deal pipelines.

Two unrelated leads landing in the same week reflects diary timing and due-diligence completion dates rather than a coordinated thesis linking Greenjets' electric propulsion to Arrakis' AI software.

What could happen next?

Meaning
Blossom Capital's back-to-back leads signal an active deployment pace at the fund rather than a thematic bet spanning propulsion hardware and AI software.

Sources:UKTN

Mentions:Arrakis →BOKA Capital →Accel →GFC →MainObject →Rerail →London →Greenjets →

First Reported In

Update #13 · Humanoid hit $1.35bn on a customer order

UKTN· 31 Jul 2026

Read original →

Causes and effects

Caused by

Greenjets raises £30m in its 21st year

Blossom Capital's lead in Arrakis followed its Greenjets lead three days earlier, the same fund backing opposite ends of the evidence spectrum.

Occurred 21 Jul 2026

Read story →

This Event

Arrakis: Blossom's second lead in 3 days

One fund led two Series A rounds in the same week at opposite ends of the evidence spectrum, and the AI company's product remains unnamed in public.

Different Perspectives

Nscale and Open Cosmos

Nscale chose the New York Stock Exchange for its listing on 18 September, putting Britain's largest AI infrastructure bet to American public investors rather than British ones. Open Cosmos took the opposite route four days earlier, raising nine figures from an all-domestic syndicate on five years of profit, evidence that staying is possible when the balance sheet allows it.

Dame Chi Onwurah and the Science, Innovation and Technology Committee

Committee chair Dame Chi Onwurah wrote to government on 7 September asking how Matt Clifford's conflict at ARIA arose and what safeguards protect its governance, and expects a detailed response. Her question has not yet been put to the Sovereign AI Unit, whose own chair sits at a venture capital firm while overseeing state AI equity.

The Entrepreneurs Network

The Entrepreneurs Network's founder survey found 65% say Britain is easy to start a business in but only 14% say it is easy to scale one, with 82% negative on tax and 74% finding investment hard to access. On this reading the constraint is regulation and tax, not the capital-vehicle design the state keeps adjusting.

New Economics Foundation

The New Economics Foundation argues fiscal accounting rules, not political will, cap what Britain's state capital vehicles can do. Matching the KfW and Bpifrance benchmark of 1% of GDP would need the National Wealth Fund to deploy roughly GBP21bn a year by 2028-29, about four times its current capacity.

Competition and Markets Authority

The CMA's 8 September report on public procurement asked whether Britain's roughly GBP400bn state-spending system is built to grow high-potential firms rather than simply widen SME participation. Its Recommendation 5 calls for a dedicated frontier-technology procurement framework, an official acknowledgement that today's design may serve the wrong target.

Highland Europe

Highland Europe, the growth-equity firm behind a €1bn-plus fund, took €65m from the British Business Bank into its Technology Growth Fund VI on 30 July via British Patient Capital. For a Geneva-based growth investor, the Bank's cheque is routine cornerstone capital, unrelated to which Whitehall department currently claims to sponsor UKRI.